综述:饮食与大肠埃希菌在炎症性肠病中的复杂相互作用
本综述通过广泛文献检索,梳理饮食成分与大肠埃希菌及其他变形菌在炎症性肠病(IBD)病因、结局和管理中的相互作用。临床前数据提示西方饮食影响大肠埃希菌的丰度、定植和表型行为,可能促进肠道炎症,而地中海饮食和特定膳食纤维可能减弱这些效应;临床试验数据有限,主要来自克罗恩病接受全肠内营养治疗的患者,溃疡性结肠炎数据稀少。作者认为在提出饮食建议前需开展设计良好的临床试验。
要点
- 临床前研究提示西方饮食及其成分可能影响大肠埃希菌的丰度、定植和表型行为,进而可能引发或促进肠道炎症。
- 地中海饮食和特定膳食纤维可能减弱上述效应并预防炎症。
- 临床试验数据有限,主要来自克罗恩病全肠内营养治疗患者,溃疡性结肠炎数据稀少;提出饮食建议前需设计良好的临床试验。
核心结论
- 临床前和一些临床试验数据提示大肠埃希菌及其他变形菌与某些饮食成分相互作用以促进肠道炎症。
- 在可提出用于疾病管理的饮食建议之前,需要设计良好的临床试验。
研究设计与样本
- 本综述进行了广泛的文献检索,以识别探索饮食成分与大肠埃希菌或变形菌相互作用机制的体外研究和动物模型研究。
- 本综述还探索了饮食和饮食疗法对IBD患者大肠埃希菌或变形菌水平的影响。
主要发现
- 临床前数据提示西方饮食及其成分影响大肠埃希菌在肠道中的丰度、定植和表型行为,这可能进而引发或促进肠道炎症。
- 地中海饮食和特定膳食纤维可能减弱这些效应并预防炎症。
- 临床试验数据有限,主要来自克罗恩病接受全肠内营养治疗的患者,研究结果常与临床前研究的观察相矛盾。
- 溃疡性结肠炎患者的数据稀少。
临床怎么用
- 作者认为在可提出用于疾病管理的饮食建议之前,需要设计良好的临床试验。
局限性
- 临床试验数据有限,主要来自克罗恩病接受全肠内营养治疗的患者。
- 溃疡性结肠炎患者的数据稀少。
- 临床试验研究结果常与临床前研究的观察相矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although no causative microbe has been yet identified or successfully targeted in the treatment of inflammatory bowel disease (IBD), the role of Escherichia coli in the pathogenesis of Crohn's disease has attracted considerable interest. AIM: In this review, we present a literature overview of the interactions between diet and E. coli and other Proteobacteria in the aetiology, outcomes and management of IBD and suggest future research directions. METHODS: An extensive literature search was performed to identify in vitro studies and research in animal models that explored mechanisms by which dietary components can interact with E. coli or Proteobacteria to initiate or propagate gut inflammation. We also explored the effect diet and dietary therapies have on the levels of E. coli or Proteobacteria in patients with IBD. RESULTS: Preclinical data suggest that the Western diet and its components influence the abundance, colonisation and phenotypic behaviour of E. coli in the gut, which may in turn initiate or contribute to gut inflammation. In contrast, the Mediterranean diet and specific dietary fibres may abrogate these effects and protect from inflammation. There are limited data from clinical trials, mostly from patients with Crohn's disease during treatment with exclusive enteral nutrition, with findings often challenging observations from preclinical research. Data from patients with ulcerative colitis are sparse. CONCLUSIONS: Preclinical and some clinical trial data suggest that E. coli and other Proteobacteria interact with certain dietary components to promote gut inflammation. Well-designed clinical trials are required before dietary recommendations for disease management can be made.
引用
- Faqerah N, Walker D, Gerasimidis K, et al. Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 37771255. doi:10.1111/apt.17720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。